metaEvidence - overview


			Statistically conclusive or suggested result	Inconclusive results	Uncertain results	Safety results
mNSCLC - L1 - PDL1 positive metastatic/advanced NSCLC (mNSCLC) - 1st line (L1) mNSCLC - L1 - PDL1 positive
versus pemetrexed plus platin
	nivolumab plus ipilimumab vs. pemetrexed plus platin	1	none	inconclusive results for: DOR; objective responses (ORR); STRAE (any grade); STRAE (grade 3-4); TRAE (grade 3-4); TRAE leading to death (grade 5); TRAE leading to discontinuation (any grade); TRAE leading to discontinuation (grade 3-4); Asthenia TRAE (grade 3-4); Constipation TRAE (grade 3-4); Decreased appetite TRAE (grade 3-4); Diarrhoea TRAE (grade 3-4); Fatigue TRAE (grade 3-4); Nausea TRAE (grade 3-4); Pruritus TRAE (grade 3-4); Rash TRAE (grade 3-4)	statistically conclusive 21 % decrease in deaths (OS) but the degree if certainty is unassessable suggested 18 % decrease in progression or deaths (PFS) but the degree if certainty is unassessable suggested 34 % decrease in TRAE (any grade) but the degree if certainty is unassessable suggested 89 % decrease in Anaemia TRAE (grade 3-4) but the degree if certainty is unassessable suggested 99 % decrease in Neutropenia TRAE (grade 3-4) but the degree if certainty is unassessable suggested 90 % decrease in Vomiting TRAE (grade 3-4) but the degree if certainty is unassessable	-